Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Lymphoma

Known as: Lymphoma (Hodgkin's and Non-Hodgkin's), Reticulolymphosarcomas, Lymphomatous 
Cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the… Expand
National Institutes of Health

Related topics

Related topics

46 relations
ATM protein, humanAtypical lymphocyteB-Cell LymphomasBUB1 gene
Expand

Narrower (7)

Immunoblastic Large-Cell LymphomaLymph Node NeoplasmLymphocytic NeoplasmLymphosarcoma Involving Spleen
Expand

Broader (2)

Lymphoid organ structureNeoplasms

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
The Potential for microRNA Therapeutics and Clinical Research
As FDA-approved small RNA drugs start to enter clinical medicine, ongoing studies for the microRNA (miRNA) class of small RNAs… Expand
  • table 1
Review
2019
Review
2019
European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders
This guideline presents recommendations for the management of coeliac disease (CD) and other gluten-related disorders both in… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Review
2019
Review
2019
Exposure to glyphosate-based herbicides and risk for non-Hodgkin lymphoma: A meta-analysis and supporting evidence.
Glyphosate is the most widely used broad-spectrum systemic herbicide in the world. Recent evaluations of the carcinogenic… Expand
  • table 1
  • table 6
  • table 8
  • table 9
  • figure 2
Review
2019
Review
2019
Clinical Applications of Arterial Spin Labeling in Brain Tumors
Abstract The aim of this review was to review the basic background, technique, and clinical applications of arterial spin… Expand
Review
2019
Review
2019
Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report
Purpose Adult T-cell leukemia-lymphoma (ATL) is a distinct mature T-cell malignancy caused by chronic infection with human T… Expand
  • table 1
  • figure 1
Review
2019
Review
2019
Properties of FDA-approved small molecule protein kinase inhibitors.
  • R. Roskoski
  • Pharmacological research
  • 2019
    • Corpus ID: 80625382
Because mutations, overexpression, and dysregulation of protein kinases play essential roles in the pathogenesis of many… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Review
2019
Review
2019
Targeting the Bcl-2 Family in B Cell Lymphoma
Although lymphoma is a very heterogeneous group of biologically complex malignancies, tumor cells across all B cell lymphoma… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Review
2019
Review
2019
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial.
BACKGROUND Sintilimab (Innovent Biologics, Suzhou, China), a highly selective, fully humanised, monoclonal antibody, blocks the… Expand
Review
2019
Review
2019
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.
PURPOSE Nivolumab, an anti-programmed death-1 monoclonal antibody, has demonstrated frequent and durable responses in relapsed… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Review
2018
Review
2018
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma
In October 2017, the FDA granted regular approval to axicabtagene ciloleucel, a CD19-directed chimeric antigen receptor (CAR) T… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE